Bavarian Nordic recently publicized positive results from a data study of its RSV vaccine candidate, MVA-BN RSV, which has shown a very good efficacy rate in its phase II study compared to the placebo.
This paves the way for a positive dialog with possible partners before a phase III study begins, says US investment bank Jeffries.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.